AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
Detroit News7d
AstraZeneca’s potential blockbuster pill halves high cholesterol
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...
BioSpace8d
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
European Medical Journal3d
AstraZeneca’s NSCLC drug approved by European Commission
The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with ...
Yahoo Finance3d
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
Also Read: FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients The approval is based on results from the DESTINY-Breast06 Phase 3 ...